Edesa Biotech Reports Favorable Mortality Reductions in COVI

Mortality reductions demonstrated across multiple patient groupsAdditional efficacy signals recorded in a broad range of mild to severe ARDS patientsCompany to focus on critically ill population for Phase

Related Keywords

Toronto , Ontario , Canada , Berlin , Germany , California , United States , United Kingdom , British , Canadian , Gary Koppenjan , Linkedin , Edesa Biotech Inc , Twitter , Nasdaq , Exchange Commission , Us Centers For Disease Control , British Columbia Securities Commission , Securities Exchange , Edesa Biotech , Safety Monitoring Board , Acute Respiratory Distress Syndrome , Hazard Ratio , Proportional Hazard Model , Respiratory Distress Syndrome , Disease Control , Securities Act , Securities Exchange Act , British Columbia Securities , Sedesa , Biotech , Reports , Favorable , Ortality , Reductions , Covid , Study ,